AMRX Q2 2022 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$559M+4.5% YoY

Gross Profit

$201M35.8% margin

Operating Income

-$199M-35.5% margin

Net Income

-$121M-21.6% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

+12.4%

Cash Flow

Operating Cash Flow

-$126M

Free Cash Flow

-$143M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$4.0B

Total Liabilities

$3.9B

Stockholders' Equity

$280M

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$559M	$535M	+4.5%
Gross Profit	$201M	$212M	-5.6%
Operating Income	-$199M	$67M	-395.9%
Net Income	-$121M	$15M	-931.3%

Revenue Segments

Generics Segment

$365M65%

Av K A R E Segment

$97M17%

Amneal Specialty Pharma Segment

$97M17%